Scroll

labetalol 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
aromatic ring -CH(-OH)-CH2-NH-R	1531	36894-69-6

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: labetalol labetalol hydrochloride albetol ibidomide labetalol HCl SCH 19927 SCH-19927	A salicylamide derivative that is a non-cardioselective blocker of BETA-ADRENERGIC RECEPTORS and ALPHA-1 ADRENERGIC RECEPTORS. Molecular weight: 328.41 Formula: C19H24N2O3 CLOGP: 2.50 LIPINSKI: 0 HAC: 5 HDO: 4 TPSA: 95.58 ALOGS: -4.75 ROTB: 8 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

labetalol
labetalol hydrochloride
albetol
ibidomide
labetalol HCl
SCH 19927
SCH-19927

A salicylamide derivative that is a non-cardioselective blocker of BETA-ADRENERGIC RECEPTORS and ALPHA-1 ADRENERGIC RECEPTORS.

Molecular weight: 328.41
Formula: C19H24N2O3
CLOGP: 2.50
LIPINSKI: 0
HAC: 5
HDO: 4
TPSA: 95.58
ALOGS: -4.75
ROTB: 8

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.60	g	O
0.60	g	P

ADMET properties:

Show entries

Search:

Property	Value	Reference
Vd (Volume of distribution)	4.80 L/kg	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	4.40 hours	Lombardo F, Berellini G, Obach RS
BA (Bioavailability)	25 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
CL (Clearance)	23 mL/min/kg	Lombardo F, Berellini G, Obach RS
EoM (Fraction excreted unchanged in urine)	2.50 %	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	16 mg/mL	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	104.53 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
fu (Fraction unbound in plasma)	0.50 %	Lombardo F, Berellini G, Obach RS

Showing 1 to 9 of 9 entries

Previous1Next

Approvals:

Date	Agency	Company	Orphan
Aug. 1, 1984	FDA	CNTY LINE PHARMS

FDA Adverse Event Reporting System (Female)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Exposure during pregnancy	205.61	14.01	165	7936	155382	63325539
Pre-eclampsia	173.92	14.01	59	8042	9074	63471847
Caesarean section	154.90	14.01	64	8037	16968	63463953
Premature baby	136.42	14.01	62	8039	20673	63460248
Premature delivery	125.41	14.01	66	8035	30215	63450706
Maternal exposure during pregnancy	93.35	14.01	127	7974	219935	63260986
Foetal growth restriction	77.62	14.01	31	8070	7522	63473399
Premature labour	59.67	14.01	30	8071	12474	63468447
Patent ductus arteriosus	49.14	14.01	19	8082	4231	63476690
Low birth weight baby	45.86	14.01	21	8080	7108	63473813

Showing 1 to 10 of 57 entries

Previous1 2 3 4 5 6Next

FDA Adverse Event Reporting System (Male)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Premature baby	151.97	17.58	67	4691	19566	34932607
Low birth weight baby	98.67	17.58	38	4720	7867	34944306
Foetal exposure during pregnancy	85.10	17.58	57	4701	38044	34914129
Anhedonia	68.84	17.58	29	4729	7556	34944617
Foetal disorder	68.46	17.58	17	4741	809	34951364
Neutropenia neonatal	60.75	17.58	15	4743	697	34951476
Foetal growth restriction	55.70	17.58	21	4737	4096	34948077
Injury	53.62	17.58	34	4724	20653	34931520
Fear	48.09	17.58	25	4733	10451	34941722
Congenital oesophageal anomaly	42.95	17.58	8	4750	93	34952080

Showing 1 to 10 of 31 entries

Previous1 2 3 4Next

FDA Adverse Event Reporting System (Geriatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Exposure during pregnancy	185.99	14.55	129	9669	101003	79633587
Pre-eclampsia	157.91	14.55	51	9747	6990	79727600
Caesarean section	122.19	14.55	49	9749	12486	79722104
Maternal exposure during pregnancy	71.58	14.55	86	9712	136452	79598138
Premature delivery	57.82	14.55	36	9762	23431	79711159
Premature labour	55.77	14.55	25	9773	8365	79726225
Anhedonia	55.77	14.55	30	9768	14868	79719722
Nephrogenic systemic fibrosis	43.01	14.55	19	9779	6141	79728449
Hypotension	42.89	14.55	135	9663	440182	79294408
Fear	42.57	14.55	29	9769	21957	79712633

Showing 1 to 10 of 52 entries

Previous1 2 3 4 5 6Next

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Show entries

Search:

Source	Code	Description
ATC	C07AG01	CARDIOVASCULAR SYSTEM BETA BLOCKING AGENTS BETA BLOCKING AGENTS Alpha and beta blocking agents
ATC	C07BG01	CARDIOVASCULAR SYSTEM BETA BLOCKING AGENTS BETA BLOCKING AGENTS AND THIAZIDES Alpha and beta blocking agents and thiazides
ATC	C07CG01	CARDIOVASCULAR SYSTEM BETA BLOCKING AGENTS BETA BLOCKING AGENTS AND OTHER DIURETICS Alpha and beta blocking agents and other diuretics
CHEBI has role	CHEBI:35530	beta-adrenergic blockers
CHEBI has role	CHEBI:35674	antihypertensive drugs
CHEBI has role	CHEBI:37890	alpha-adrenergic receptor blockaders
CHEBI has role	CHEBI:66991	sympatholytic drug
FDA EPC	N0000175556	beta-Adrenergic Blocker
FDA MoA	N0000000161	Adrenergic beta-Antagonists
MeSH PA	D018663	Adrenergic Agents

Showing 1 to 10 of 19 entries

Previous1 2Next

Drug Use | Suggest Off label Use Form| |View source of the data|

Show entries

Search:

Disease	Relation	SNOMED_ID	DOID
Hypertensive disorder	indication	38341003	DOID:10763
Angina pectoris	off-label use	194828000
Pheochromocytoma Adjunct Therapy	off-label use
Anuria	contraindication	2472002	DOID:2983
Bronchospasm	contraindication	4386001
Hypercholesterolemia	contraindication	13644009
Secondary angle-closure glaucoma	contraindication	21571006
Complete atrioventricular block	contraindication	27885002
Hypovolemia	contraindication	28560003
Dehydration	contraindication	34095006

Showing 1 to 10 of 36 entries

Previous1 2 3 4Next

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	8.81	acidic
pKa2	12.65	acidic
pKa3	8.23	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Show entries

Search:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Beta-1 adrenergic receptor	GPCR	P08588	ADRB1_HUMAN	ANTAGONIST	Ki	8.23	DRUG MATRIX	CHEMBL
Beta-2 adrenergic receptor	GPCR	P07550	ADRB2_HUMAN	ANTAGONIST	Ki	7.96	DRUG MATRIX	CHEMBL
Sigma non-opioid intracellular receptor 1	Membrane receptor	Q99720	SGMR1_HUMAN		Ki	6.12	DRUG MATRIX
Sodium-dependent noradrenaline transporter	Transporter	P23975	SC6A2_HUMAN		Ki	5.48	DRUG MATRIX
5-hydroxytryptamine receptor 1A	GPCR	P08908	5HT1A_HUMAN		Ki	6.65	DRUG MATRIX
5-hydroxytryptamine receptor 2B	GPCR	P41595	5HT2B_HUMAN		Ki	5.71	DRUG MATRIX
Sodium-dependent dopamine transporter	Transporter	Q01959	SC6A3_HUMAN		Ki	5.89	DRUG MATRIX
Cytochrome P450 2D6	Enzyme	P10635	CP2D6_HUMAN		IC50	6.10	DRUG MATRIX
Alpha-1D adrenergic receptor	GPCR	P25100	ADA1D_HUMAN	ANTAGONIST	Ki	7.64	DRUG MATRIX
Alpha-1B adrenergic receptor	GPCR		ADA1B_RAT		Ki	6.49	DRUG MATRIX

Showing 1 to 10 of 14 entries

Previous1 2Next

External reference:

Show entries

Search:

ID	Source
001839	NDDF
004368	NDDF
11828	MMSL
201477	MMSL
202693	RXNORM
32780-64-6	SECONDARY_CAS_RN
372750000	SNOMEDCT_US
3869	PUBCHEM_CID
3941	INN_ID
4018799	VANDF

Showing 1 to 10 of 27 entries

Previous1 2 3Next

Pharmaceutical products:

Show entries

Search:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Labetalol HCl	HUMAN PRESCRIPTION DRUG LABEL	1	0185-0010	TABLET, FILM COATED	100 mg	ORAL	ANDA	23 sections
Labetalol HCl	HUMAN PRESCRIPTION DRUG LABEL	1	0185-0117	TABLET, FILM COATED	200 mg	ORAL	ANDA	23 sections
Labetalol HCl	HUMAN PRESCRIPTION DRUG LABEL	1	0185-0118	TABLET, FILM COATED	300 mg	ORAL	ANDA	23 sections
Labetalol HCL	HUMAN PRESCRIPTION DRUG LABEL	1	0615-8130	TABLET, FILM COATED	100 mg	ORAL	ANDA	22 sections
Labetalol HCL	HUMAN PRESCRIPTION DRUG LABEL	1	0615-8131	TABLET, FILM COATED	200 mg	ORAL	ANDA	22 sections
Labetalol HCl in Dextrose	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9366	INJECTION	1 mg	INTRAVENOUS	NDA	24 sections
Labetalol HCl in Dextrose	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9366	INJECTION	1 mg	INTRAVENOUS	NDA	24 sections
Labetalol HCl in Sodium Chloride	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9363	INJECTION	1 mg	INTRAVENOUS	NDA	24 sections
Labetalol HCl in Sodium Chloride	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9363	INJECTION	1 mg	INTRAVENOUS	NDA	24 sections
Labetalol HCl in Sodium Chloride	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9364	INJECTION	1 mg	INTRAVENOUS	NDA	24 sections

Showing 1 to 10 of 30 entries

Previous1 2 3Next